Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - prevention - patients without history of AF (primary prevention)

Related trials

GISSI HF (subgroup and ancillary study), 2009 - rosuvastatin vs placebo

ARMYDA-3 (AF ancillary study), 2006 - atorvastatin vs placebo

Chello, 2006 - atorvastatin vs placebo

LIFE (AF ancillary study), 2005 - losartan vs atenolol

CHARM (AF ancillary study), 2005 - candesartan vs placebo

Val-HeFT (AF ancillary study), 2003 - valsartan vs placebo

GISSI-3 (AF ancillary study), 2003 - lisinopril vs placebo

SOLVD (AF ancillary study), 2003 - enalapril vs placebo

MIRACL (AF ancillary study), 2001 - atorvastatin vs placebo

TRACE (AF ancillary study), 1999 - trandolapril vs placebo

VA HIT (AF ancillary study), 1999 - gemfibrozil vs placebo

See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of prevention
  • All clinical trials of enalapril
     SOLVD (AF ancillary study) study, 2003 TRC9795 
    download pdf: enalapril | prevention for atrial fibrillation


    Studied treatment enalapril
    Control treatment placebo


    Patients Heart failure
    Inclusion criteria patient with history of AF excluded; sinus rhythm at baseline

    Method and design

    Randomized effectives 186 / 188 (studied vs. control)
    Follow-up duration 2.9 y


    Endpoint Studied treat.
    Control treat.
    Graph RR [95% CI]

    atrial fibrillation

    10 / 186
    45 / 188
    0,22 [0,12;0,43]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Studied treat. Control treat.
    atrial fibrillation 10 / 186 (5,4%) 45 / 188 (23,9%) 0,22 [0,12;0,43]   11053
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11053: Anand K, Mooss AN, Hee TT, Mohiuddin SMMeta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.Am Heart J 2006;152:217-22

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 2.9 y)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 5,38% 23,94% -18,56%

    Meta-analysis of all similar trials:

    prevention in atrial fibrillation for patients without history of AF (primary prevention)


    TrialResults-center ID TRC9795
    Trials register # NA
    • Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.. Circulation 2003;107:2926-31 - 10.1161/01.CIR.0000072793.81076.D4
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels